新华网财经观察丨“全勤生”的进博之约

Core Points - The 8th China International Import Expo (CIIE) is being held in Shanghai from November 5 to 10, with participation from 155 countries and regions, showcasing 4,108 foreign enterprises [2] - 170 companies and 27 institutions have been consistent participants over the years, demonstrating their commitment to the Chinese market and the benefits of China's ongoing opening-up [2][3] - The expo has evolved beyond a simple trade fair to become a platform for foreign companies to showcase their strength and long-term commitment in China, reflecting their confidence in the Chinese market [2] Group 1: Company Participation and Perspectives - Qualcomm's booth emphasizes collaboration with Chinese partners, showcasing the integration of 5G and AI technologies, highlighting ongoing innovation [5] - Siemens views the expo as a platform for deep interaction between China and the world, aiming to integrate AI into industrial applications to enhance digitalization and decarbonization efforts in China [8] - Sanofi has consistently participated in the expo, seeing it as a bridge for cooperation and a testament to China's expanding openness [6] Group 2: Innovation and Market Dynamics - ABB's local R&D efforts in China have led to significant innovations, showcasing the country's potential as a hub for global innovation [11] - Varian Medical's participation illustrates the expo's role as an accelerator for global innovation, enabling rapid market entry for advanced technologies in China [12] - Bayer emphasizes China's role as a core market for global innovation, with the expo facilitating faster access for innovative products [13] Group 3: Economic Environment and Future Outlook - The 14th Five-Year Plan emphasizes expanding institutional openness and maintaining a multilateral trade system, which is expected to attract more foreign investment [14] - General Electric acknowledges improvements in China's business environment and the increasing openness to foreign investment, reinforcing confidence in long-term development in China [16] - AstraZeneca's ongoing commitment to the Chinese market reflects the company's strategy to leverage opportunities and enhance health outcomes in China [17]